StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning.
Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th.
View Our Latest Analysis on BioLineRx
BioLineRx Stock Performance
BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $4.80 million during the quarter, compared to analyst estimates of $0.17 million. During the same period in the previous year, the company posted ($0.09) earnings per share. Analysts expect that BioLineRx will post -1.03 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BLRX. PVG Asset Management Corp purchased a new position in BioLineRx in the 4th quarter valued at about $97,000. Values First Advisors Inc. purchased a new position in BioLineRx in the 3rd quarter valued at about $88,000. Rathbones Group PLC purchased a new position in BioLineRx in the 3rd quarter valued at about $72,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new position in BioLineRx in the 3rd quarter valued at about $46,000. Finally, NorthRock Partners LLC purchased a new position in BioLineRx in the 4th quarter valued at about $27,000. 1.56% of the stock is currently owned by hedge funds and other institutional investors.
BioLineRx Company Profile
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
Further Reading
- Five stocks we like better than BioLineRx
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Stocks Leading the U.S. Agriculture Comeback
- Consumer Staples Stocks, Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.